Scandion Oncology (Sweden) Performance
| SCOL Stock | SEK 0.07 0 1.43% |
The entity has a beta of -1.48, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Scandion Oncology are expected to decrease by larger amounts. On the other hand, during market turmoil, Scandion Oncology is expected to outperform it. At this point, Scandion Oncology has a negative expected return of -1.02%. Please make sure to validate Scandion Oncology's coefficient of variation, information ratio, total risk alpha, as well as the relationship between the standard deviation and jensen alpha , to decide if Scandion Oncology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Scandion Oncology AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 5.8 M | |
| Total Cashflows From Investing Activities | -485 K |
Scandion |
Scandion Oncology Relative Risk vs. Return Landscape
If you would invest 15.00 in Scandion Oncology AS on August 31, 2024 and sell it today you would lose (7.90) from holding Scandion Oncology AS or give up 52.67% of portfolio value over 90 days. Scandion Oncology AS is generating negative expected returns and assumes 5.2388% volatility on return distribution over the 90 days horizon. Simply put, 46% of stocks are less volatile than Scandion, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Scandion Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Scandion Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Scandion Oncology AS, and traders can use it to determine the average amount a Scandion Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1955
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SCOL |
Estimated Market Risk
| 5.24 actual daily | 46 54% of assets are more volatile |
Expected Return
| -1.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.2 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Scandion Oncology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Scandion Oncology by adding Scandion Oncology to a well-diversified portfolio.
Scandion Oncology Fundamentals Growth
Scandion Stock prices reflect investors' perceptions of the future prospects and financial health of Scandion Oncology, and Scandion Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Scandion Stock performance.
| Return On Equity | -0.74 | |||
| Return On Asset | -0.42 | |||
| Operating Margin | 473.28 % | |||
| Current Valuation | (6.85 M) | |||
| Shares Outstanding | 40.71 M | |||
| Price To Book | 1.01 X | |||
| Price To Sales | 969.63 X | |||
| EBITDA | (55.84 M) | |||
| Cash And Equivalents | 131.54 M | |||
| Cash Per Share | 4.09 X | |||
| Book Value Per Share | 2.10 X | |||
| Cash Flow From Operations | (49.8 M) | |||
| Earnings Per Share | (1.74) X | |||
| Total Asset | 116.22 M | |||
About Scandion Oncology Performance
Assessing Scandion Oncology's fundamental ratios provides investors with valuable insights into Scandion Oncology's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Scandion Oncology is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Scandion Oncology AS, a biotechnology company, develops drugs for the treatment of chemotherapy resistance in cancer patients. The company was founded in 2017 and is based in Copenhagen, Denmark. Scandion Oncology operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 6 people.Things to note about Scandion Oncology performance evaluation
Checking the ongoing alerts about Scandion Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Scandion Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Scandion Oncology generated a negative expected return over the last 90 days | |
| Scandion Oncology has high historical volatility and very poor performance | |
| Scandion Oncology has some characteristics of a very speculative penny stock | |
| Scandion Oncology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (51.7 M) with loss before overhead, payroll, taxes, and interest of (32.32 M). | |
| Scandion Oncology AS has accumulated about 131.54 M in cash with (49.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Scandion Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Scandion Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Scandion Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Scandion Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Scandion Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Scandion Oncology's stock. These opinions can provide insight into Scandion Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Scandion Stock Analysis
When running Scandion Oncology's price analysis, check to measure Scandion Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandion Oncology is operating at the current time. Most of Scandion Oncology's value examination focuses on studying past and present price action to predict the probability of Scandion Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandion Oncology's price. Additionally, you may evaluate how the addition of Scandion Oncology to your portfolios can decrease your overall portfolio volatility.